Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Investors
**Shareholders' Meeting**
Gli Azionisti approvano tutte le mozioni del Consiglio di Amministrazione
Milano - 6 aprile 2010 - Newron Pharmaceuticals SpA annuncia che l' Assemblea dei Soci (in sessione ordinaria e straordinaria), tenutasi a Bresso (Milano) in seconda convocazione il 2 Aprile 2010, ha approvato tutte le mozioni proposte dal Consiglio di Amministrazione. L' incarico di controllo e revisione contabile per la certificazione relativa agli anni finanziari 2010, 2011 e 2012 e' stato conferito alla societa' Reconta Ernst & Young SpA. Il mandato dei tre membri permanenti del Collegio Sindacale e' stato confermato per altri 3 anni.
********************
Shareholders approve all motions of the Board of Directors
Milan, Italy - April 6, 2010 - Newron Pharmaceuticals S.p.A. announces that at its Ordinary and Extraordinary General Meetings held in Bresso/Milan on April 2, 2010 all motions proposed by the Board of Directors were approved. The mandate for the accounting control and external auditing for certification relating to the financial years 2010, 2011 and 2012 was granted to Reconta Ernst & Young S.p.A. The three permanent members of the Board of Statutory Auditors were confirmed for another 3-year-mandate, as well.